{"product_id":"annexonbio-business-model-canvas","title":"Annexon Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the full Business Model Canvas for strategic benchmarking and growth planning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Annexon’s strategic playbook with our full Business Model Canvas — three to five sentences won’t cut it, but this downloadable file lays out value propositions, customer segments, revenue streams, and growth levers in actionable detail. Ideal for investors, founders, and analysts, it’s ready for benchmarking and strategic planning. Purchase the complete Canvas to convert insight into advantage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic \u0026amp; Medical Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with leading neurology and immunology academic and medical centers accelerate discovery and translational studies and in 2024 produced peer-reviewed co-authorships that strengthen data credibility. These sites provide access to deeply phenotyped patient populations and biobanks, enabling rapid identification of biomarkers. They also enable faster first-in-human and proof-of-concept trials, shortening timelines to clinical readouts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Research \u0026amp; Manufacturing (CRO\/CDMO)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal CROs manage trial operations, site monitoring and data integrity while CDMOs supply GMP drug substance and drug product at scale; the combined CRO\/CDMO market exceeded roughly $80 billion in 2024. These partners compress timelines—outsourcing can cut development time by up to 30%—and shift fixed costs to variable spend. They also deliver CMC expertise for scale-up and validation, de‑risking commercial readiness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma Co-development \u0026amp; Licensing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStrategic co-development and licensing alliances expand indications and geographic reach, enabling Annexon to leverage partners' global regulatory and commercial networks; large biopharma deals in 2024 commonly included upfronts and milestones exceeding $100M. Partners share development risk and fund pivotal studies, reducing cash burn and extending runway. Co-promotion aligns incentives in key markets, while milestones and royalties (commonly 5–15%) provide non-dilutive financing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; HTA Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly dialogue with FDA, EMA and major HTA bodies shapes endpoints and comparators, with parallel scientific advice now routinely used to align trials to regulatory and payer expectations; this approach has been linked to higher approval predictability and smoother market access in 2024. Coordinated consultations clarify evidence needs and de‑risk approval pathways, supporting pricing and access plans.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly FDA\/EMA engagement\u003c\/li\u003e\n\u003cli\u003eParallel HTA\/payer consultation\u003c\/li\u003e\n\u003cli\u003eScientific advice reduces approval risk\u003c\/li\u003e\n\u003cli\u003eAlignment supports pricing\/access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy \u0026amp; Registries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient advocacy groups boost trial awareness and can shorten recruitment timelines by up to 30%, improving enrollment for rare neurodegenerative studies. Registries provide natural-history datasets—by 2024 they aggregated tens of thousands of patient records—supporting endpoint selection and burden-of-illness analyses. Ongoing engagement enhances adherence and enables real-world outcomes research.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdvocacy-driven recruitment: faster enrollment, improved retention\u003c\/li\u003e\n\u003cli\u003eRegistries: tens of thousands of patient records by 2024\u003c\/li\u003e\n\u003cli\u003eData use: informs endpoints and burden-of-illness\u003c\/li\u003e\n\u003cli\u003eEngagement: supports adherence and outcomes research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology partnerships speed biomarkers; CRO\/CDMO shave \u003cstrong\u003e30%\u003c\/strong\u003e, deals \u0026gt;$100M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with top neurology centers produced 2024 peer‑reviewed co‑authorships and access to tens of thousands of registry records, accelerating biomarker discovery and FIH trials. CRO\/CDMO partners (global market ~$80B in 2024) cut development time up to 30% and de‑risk CMC. Licensing deals in 2024 commonly featured \u0026gt;$100M upfront\/milestones with royalties ~5–15%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic centers\u003c\/td\u003e\n\u003ctd\u003eBiomarkers\/trials\u003c\/td\u003e\n\u003ctd\u003etens of thousands records\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRO\/CDMO\u003c\/td\u003e\n\u003ctd\u003eOps\/CMC\u003c\/td\u003e\n\u003ctd\u003e$80B market; ≤30% time cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma\u003c\/td\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$100M deals; 5–15% royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas tailored to Annexon, covering the 9 BMC blocks—customer segments, channels, value propositions, revenue and cost structures—with narratives, competitive advantages and SWOT tied to real-world operations, ideal for investor presentations and strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level snapshot of Annexon’s business model in editable cells, condensing strategy into a one-page format that saves hours of structuring while enabling fast comparisons, team collaboration, and quick executive review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Development Execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesign and run Phase 1–3 trials targeting complement-mediated neurodegeneration with adaptive protocols and biomarker-driven endpoints (C3\/C5, neurofilament light); 2024 industry benchmarks place CNS Phase 3 costs near $100–200M and median enrollment 300–1,000 patients. Optimize inclusion criteria\/endpoints to reduce 60% screen-failure rates, ensure GCP, centralized data quality and DSMB safety oversight, and manage site activation, enrollment projections, and planned interim analyses for futility and efficacy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC \u0026amp; Manufacturing Scale-Up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDevelop robust processes for C1q-targeting therapeutics leveraging established antibody biologics platforms. Validate analytical methods per ICH Q2(R1) and implement stability programs following ICH Q1A(R2). Scale from clinical to commercial supply under GMP and conduct PPQ with three consecutive commercial-scale lots as per FDA guidance. Prepare tech transfer with finalized batch records, specifications and comparability data for commercial sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Strategy \u0026amp; Submissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePlan regulatory pathways targeting Fast Track and Breakthrough designations and US Orphan Drug status, which confers 7 years of US market exclusivity; prioritize pre-IND and pre-BLA meetings to align on endpoints. Compile INDs\/CTAs and eventual BLAs\/MAAs with PDUFA review goals of 10 months (standard) or 6 months (priority). Maintain pharmacovigilance and RMP\/PSUR systems for ongoing safety monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker \u0026amp; Companion Diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eValidate C1q\/complement activity biomarkers to demonstrate target engagement and correlate biomarker changes with clinical outcomes; as of 2024 Annexon embeds C1q readouts as primary pharmacodynamic endpoints in clinical protocols.\u003c\/p\u003e\n\u003cp\u003eDevelop robust, quantitative assays for patient stratification and integrate them into trial designs to de-risk efficacy readouts, reduce variability, and enhance responder identification.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAs of 2024: C1q PD endpoints included in pivotal\/phase II protocols\u003c\/li\u003e\n\u003cli\u003eAssay development focused on quantitative, reproducible stratification\u003c\/li\u003e\n\u003cli\u003eBiomarker integration aimed to improve signal detection and reduce trial risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP Management \u0026amp; KOL Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStrengthen Annexon’s patent estate around anti-C1q biology, formulations, and methods by filing continuations and global counterparts and coordinating prosecution to close identified gaps in freedom-to-operate.\u003c\/p\u003e\n\u003cp\u003eContinuously monitor FTO landscapes and prosecute internationally to secure market exclusivity while mitigating competitor risks and clearance delays.\u003c\/p\u003e\n\u003cp\u003eBuild KOL advocacy through targeted publications and symposia, translating their clinical insights into adaptive trial designs and accelerating clinical adoption pathways.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent filings: global prosecution focus\u003c\/li\u003e\n\u003cli\u003eFTO monitoring: ongoing\u003c\/li\u003e\n\u003cli\u003eKOL engagement: publications + symposia\u003c\/li\u003e\n\u003cli\u003eTranslate insights: trial design \u0026amp; adoption\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdaptive Phase 1-3 trials for complement neurodegeneration: C1q PD, stratification, GMP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign and run adaptive Phase 1–3 trials for complement-mediated neurodegeneration (2024 benchmarks: Phase 3 cost $100–200M, median enrollment 300–1,000; 60% screen-failure). Embed C1q PD endpoints and quantitative stratification assays to de-risk readouts. Scale GMP supply with PPQ (3 commercial lots) and global patent prosecution. Maintain regulatory strategy (Fast Track\/Breakthrough\/Orphan) and KOL advocacy.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document previewed here is the exact Annexon Business Model Canvas you’ll receive—this is not a mockup or sample. Upon purchase you’ll instantly download the complete, editable file formatted the same way shown here. No hidden pages, no filler—ready to present, edit, or share in Word and Excel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eC1q-Centric IP Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnnexon’s C1q-centric IP portfolio centers on patents protecting anti-C1q targets, antibodies and uses in neurodegeneration, anchored by the ANX005 program in clinical development as of 2024. Proprietary trade secrets cover assay development and manufacturing processes. Global patent filings target major markets and defensive publications are used to limit competitor freedom to operate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific \u0026amp; Clinical Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eExperienced immunology, neurology and development teams drive Annexon’s translational pipeline, with cross-functional expertise in translational medicine and biostatistics supporting program design. Leadership has navigated late-stage clinical milestones through 2024, maintaining operational oversight of pivotal trials. Field medical structure includes MSLs and medical directors focused on HCP engagement and investigator support.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical \u0026amp; Biomarker Data Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn 2024 Annexon consolidated integrated datasets spanning preclinical and clinical studies to support target validation and translational analyses. Longitudinal biomarker panels are linked to clinical outcomes to inform dose and endpoint selection. Curated natural history comparators augment trial interpretation. Cloud-native data infrastructure enables rapid analyses and regulatory-ready submissions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP Manufacturing Know-how\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnnexon’s GMP manufacturing know-how covers process development for complement-targeting biologics with platform purification workflows and 2024-standard release analytics (typically \u0026gt;20 validated assays) under ISO\/GMP-validated quality systems. Established supply-chain relationships with multiple vendors for critical raw materials mitigate single-supplier risk. Scalability plans include scale-up to 2,000L bioreactors and modular capacity expansion for commercial demand.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProcess dev: platform purification\u003c\/li\u003e\n\u003cli\u003eQuality: ISO\/GMP, \u0026gt;20 assays (2024)\u003c\/li\u003e\n\u003cli\u003eSupply: multi-vendor sourcing\u003c\/li\u003e\n\u003cli\u003eScale: up to 2,000L modular capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital \u0026amp; Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAnnexon maintains capital and strategic partnerships that secure cash runway to advance clinical milestones, leverage non-dilutive grants and milestone payments, and draw on a syndicate of supportive investors to reduce dilution risk. Partner networks enable co-development pathways and facilitate market access through established commercialization channels, accelerating late-stage development and potential licensing opportunities.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash runway supports clinical milestones\u003c\/li\u003e\n\u003cli\u003eAccess to non-dilutive grants and milestone payments\u003c\/li\u003e\n\u003cli\u003eSyndicate of supportive investors\u003c\/li\u003e\n\u003cli\u003ePartner networks for co-development and market access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eC1q-centric IP and clinical-stage complement inhibitor with biomarker-led translational platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnnexon’s key resources include a C1q-centric IP portfolio anchored by ANX005 in clinical development (2024), proprietary assays and trade secrets, and experienced immunology\/neurology development teams. Integrated preclinical\/clinical datasets and cloud-native infrastructure support translational analysis and biomarker-driven endpoints. GMP manufacturing capabilities feature platform purification, \u0026gt;20 validated release assays (2024) and scale plans to 2,000L; strategic partners and investor syndicate secure funding.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey data (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP\u003c\/td\u003e\n\u003ctd\u003eANX005 clinical program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAssays\/Data\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;20 validated assays; longitudinal biomarker panels\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003ePlatform purification; scale to 2,000L\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinance\/Partners\u003c\/td\u003e\n\u003ctd\u003eInvestor syndicate; co-development networks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted C1q Inhibition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBlocks the initiating step of the classical complement pathway by binding C1q. Aims to prevent synaptic loss and destructive inflammation in neurodegenerative and autoimmune indications. Offers mechanistic specificity versus broad complement blockade, potentially improving risk-benefit. ANX005 was in Phase 2 clinical development as of 2024, supporting translational validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDisease-Modification Potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigned to target underlying pathophysiology, Annexon’s candidates aim to slow or halt neurodegeneration rather than only treat symptoms; recent DMT evidence (eg, lecanemab showed ~27% slowing of clinical decline in phase 3) demonstrates this potential. With 6.7 million Americans living with Alzheimer’s in 2024, disease modification could preserve function and quality of life and support more durable clinical and economic outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker-Driven Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBiomarker-driven development uses validated biomarkers to demonstrate target engagement, translating into up to 2x higher technical and regulatory probability of success versus non-stratified programs. It enables patient stratification and adaptive designs that can reduce required enrollment by up to 50%, shortening timelines and lowering costs. This approach also generates payer-relevant evidence for value-based pricing and reimbursement negotiations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare \u0026amp; High-Unmet Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAnnexon targets indications where about 95% of rare diseases lack an FDA-approved therapy (NORD), enabling strong unmet-need positioning. Orphan Drug Act incentives deliver 7-year US market exclusivity, supporting commercial upside and investor returns. Focused, biomarker-driven cohorts allow streamlined trials with smaller N and faster readouts, creating clear value narratives for payers and providers.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% no approved therapy (NORD)\u003c\/li\u003e\n\u003cli\u003e7-year US orphan exclusivity\u003c\/li\u003e\n\u003cli\u003eSmaller, biomarker-defined trials\u003c\/li\u003e\n\u003cli\u003eClear payer\/provider value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCombination \u0026amp; Line-Extension Options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eComplement-targeting mechanism is designed to be co-administered with standard of care and other neuroprotectives, enabling add-on trials and combination labels. Platform supports multiple neurodegenerative indications, addressing patient populations in the millions and broadening addressable market. Lifecycle management via formulation, dosing and post-approval geographic and label expansions can drive incremental revenue and peak sales upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCombination-ready\u003c\/li\u003e\n\u003cli\u003eMulti-indication reach\u003c\/li\u003e\n\u003cli\u003eLifecycle levers: formulation\/dosing\u003c\/li\u003e\n\u003cli\u003eGeographic \u0026amp; label expansion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eC1q blockade targets AD disease modification; \u003cstrong\u003e6.7M\u003c\/strong\u003e US cases (2024)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBlocks C1q to prevent synaptic loss and inflammation; ANX005 in Phase 2 as of 2024. Aims disease modification in AD where 6.7M Americans lived with disease in 2024, supporting durable clinical\/economic value. Biomarker-driven, stratified trials can halve enrollment and double technical\/regulatory success. Orphan focus: 95% of rare diseases lack FDA therapy; 7-year US exclusivity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eANX005 status (2024)\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS AD prevalence (2024)\u003c\/td\u003e\n\u003ctd\u003e6.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare diseases w\/o therapy\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan exclusivity\u003c\/td\u003e\n\u003ctd\u003e7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist HCP Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDeep ties with neurologists (approximately 20,000 US neurologists) and related specialists are maintained via MSL-led education, CME programs and transparent data-sharing; a common MSL coverage ratio (~1:100 HCPs) enables rapid clinic-to-development feedback and measurable initiation\/adherence support, with patient-support pathways targeting double-digit adherence gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCenter of Excellence Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmbed partnerships at high-volume referral hubs including 72 NCI-designated centers and 155 US medical schools (2024) to accelerate enrollment and protocol refinement. Joint protocol development and investigator-led studies across these centers enable standardized shared registries and longitudinal outcomes tracking. Co-authoring multicenter publications amplifies credibility and peer-reviewed visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer \u0026amp; HTA Collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDevelop early value dossiers and 3–5 year budget impact models for payers and HTAs to quantify short- and mid-term fiscal effects. Pursue outcomes-based contracting where clinically measurable endpoints allow risk-sharing and align pricing to performance. Implement real-world evidence generation via registries and claims linkage to validate effectiveness and safety. Maintain transparent communication on clinical differentiation using absolute risk reduction and NNT metrics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatient Support Programs provide onboarding, financial assistance, and nursing support to expedite therapy start; 2024 industry data show PSPs can improve adherence by up to 20% and reduce infusion no-shows by ~15%. Tools include digital reminders, infusion coordination, and education on disease and therapy expectations, with multi-channel feedback loops to refine experience.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOnboarding \u0026amp; nursing\u003c\/li\u003e\n\u003cli\u003eFinancial aid \u0026amp; cost navigation\u003c\/li\u003e\n\u003cli\u003eAdherence tools \u0026amp; infusion coordination\u003c\/li\u003e\n\u003cli\u003ePatient education\u003c\/li\u003e\n\u003cli\u003eFeedback channels for continuous improvement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital \u0026amp; Community Outreach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpannexon leverages patient portals and hcp platforms to centralize resources using accessed by roughly of us adults per onc reports scales education via webinars with average attendance while virtual advisory boards extend global clinician input social listening pinpoints unmet needs across rare disease communities affecting million people worldwide enabling tailored content engagement.\u003e\n\u003cul class=\"lst_crct\"\u003e\u003c\/ul\u003e\n\u003cli\u003ePatient portals: 60% US adults (ONC)\u003c\/li\u003e\n\u003cli\u003eWebinar attendance: ~41% (ON24)\u003c\/li\u003e\n\u003cli\u003eRare disease reach: ~300 million globally (WHO)\u003c\/li\u003e\n\u003clabel\u003e\u003c\/label\u003e\n\u003c\/pannexon\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMSL network reaches \u003cstrong\u003e~20,000\u003c\/strong\u003e neurologists; \u003cstrong\u003e72\u003c\/strong\u003e NCI \u0026amp; \u003cstrong\u003e155\u003c\/strong\u003e med schools accelerate trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMSL-led education and MSL:HCP ~1:100 sustain ties with ~20,000 US neurologists and specialists, enabling rapid clinic-to-development feedback. Partnerships with 72 NCI centers and 155 US medical schools (2024) accelerate enrollment and registries. PSPs (2024) target +20% adherence and −15% infusion no-shows; payer dossiers and RWE support outcomes-based contracting.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS neurologists engaged\u003c\/td\u003e\n\u003ctd\u003e~20,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCI centers\u003c\/td\u003e\n\u003ctd\u003e72\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS medical schools\u003c\/td\u003e\n\u003ctd\u003e155\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePSP adherence impact\u003c\/td\u003e\n\u003ctd\u003e+20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusion no-show reduction\u003c\/td\u003e\n\u003ctd\u003e−15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient portal use (US)\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWebinar avg attendance\u003c\/td\u003e\n\u003ctd\u003e41%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease reach\u003c\/td\u003e\n\u003ctd\u003e~300M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Distribution \u0026amp; Infusion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLimited biologics cold-chain capacity constrains distribution, even as specialty medicines account for over 50% of US drug spend in 2024 (IQVIA); Annexon relies on hospital and ambulatory infusion centers for administration to ensure clinical oversight. HUB services perform benefits verification and copay support, while streamlined prior authorization workflows aim to cut typical authorization delays that often postpone treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eField Medical \u0026amp; Sales Teams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eField medical deploys MSLs for scientific exchange and study support while key account managers engage COEs and IDNs; access strategy is aligned to payer policies to secure coverage in a global pharma market of about $1.6 trillion in 2024, supported by responsive field tools and real‑time dashboards for HCP engagement and reimbursement tracking.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScientific Conferences \u0026amp; Journals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePresent Phase data at major neurology and immunology congresses such as AAN (~12,000 attendees) and ECTRIMS (~9,000), targeting clinicians and KOLs with posters and oral sessions. Publish in high-impact, peer-reviewed outlets (impact factor \u0026gt;10) to validate efficacy and safety. Host satellite symposia (typical budget $50k–$150k) to educate KOLs and gather feedback. Amplify results via earned media and targeted press outreach to 100+ clinical and trade outlets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdigital medical education delivers on-demand modules live webinars and case studies with accredited cme partnerships leveraging interactive biomarker interpretation tools analytics to refine content boost clinician engagement in of clinicians preferred formats digital adoption grew year-over-year.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eOn-demand modules\u003c\/li\u003e\u003cli\u003eAccredited CME partnerships\u003c\/li\u003e\u003cli\u003eInteractive biomarker tools\u003c\/li\u003e\u003cli\u003eContent analytics for iteration\u003c\/li\u003e\n\u003c\/pdigital\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePartnership \u0026amp; Licensing \u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003ePartnership \u0026amp; Licensing drives regional commercialization for Annexon by leveraging local biologics partners to accelerate market entry for complement-targeted candidates; co-promotion agreements focus on priority markets like the US and EU to expand reach and reduce fixed commercial spend.\u003c\/p\u003e\n\u003cp\u003eManaged access programs are implemented in markets with unmet need to ensure early patient access while milestone-driven collaboration plans align R\u0026amp;D and commercial payments to de-risk timelines and link partner payouts to regulatory and sales milestones.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eregional commercialization\u003c\/li\u003e\n\u003cli\u003eco-promotion in priority markets\u003c\/li\u003e\n\u003cli\u003emanaged access programs\u003c\/li\u003e\n\u003cli\u003emilestone-driven collaboration plans\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfusion\/HUB + field\/scientific expand access; specialty spend \u0026gt; \u003cstrong\u003e50%\u003c\/strong\u003e\n\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAnnexon channels combine hospital\/ambulatory infusion capacity with HUB services for benefits verification and prioritization of prior authorizations, addressing cold-chain limits as specialty medicines exceed 50% of US drug spend in 2024 (IQVIA). Field medical\/MSLs and KAMs target COEs\/IDNs aligned to payer policies in a ~$1.6T pharma market (2024). Scientific dissemination leverages AAN (12k) and ECTRIMS (9k), high-impact journals, satellite symposia ($50k–$150k), and digital CME (68% prefer on-demand in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusion\/HUB\u003c\/td\u003e\n\u003ctd\u003eCoverage\/authorization\u003c\/td\u003e\n\u003ctd\u003e50%+ US spend; streamlined PA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eField\u003c\/td\u003e\n\u003ctd\u003eMarket reach\u003c\/td\u003e\n\u003ctd\u003e$1.6T pharma market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eScientific\u003c\/td\u003e\n\u003ctd\u003eCongress attendees\u003c\/td\u003e\n\u003ctd\u003eAAN 12k; ECTRIMS 9k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital CME\u003c\/td\u003e\n\u003ctd\u003eClinician preference\u003c\/td\u003e\n\u003ctd\u003e68% on-demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurologists \u0026amp; Subspecialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNeurologists and subspecialists are primary prescribers for neurodegenerative diseases such as Alzheimer disease (6.7 million Americans aged 65+ in 2024) and Parkinson disease (~1.2 million US in 2024), shaping treatment protocols and adoption; they require robust randomized controlled trial evidence consistent with FDA expectations (pivotal multicenter trials) and clear safety profiles with long‑term follow‑up (≥12 months), and value streamlined initiation and monitoring pathways that preserve clinic throughput.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals \u0026amp; Centers of Excellence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals and Centers of Excellence, led by Pharmacy \u0026amp; Therapeutics committees and clinical pathway directors, are primary decision-makers for formulary and pathway inclusion. These sites concentrate eligible patient cohorts—across ≈6,000 US hospitals and \u0026gt;150 academic centers—facilitating efficient enrollment and referral. Most have the infrastructure for complex biologics and tap EHR\/data partners (EHR adoption ≈96%) for outcomes tracking and real-world evidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayers \u0026amp; HTA Bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePayers and HTA bodies control coverage and reimbursement, applying cost-effectiveness thresholds (eg NICE £20–30k\/QALY) and demanding demonstration of unmet need—around 95% of rare diseases still lack approved therapies. They increasingly require real-world outcomes and durability data for value dossiers and risk-sharing, with budget-impact models typically assessed over 3–5 years to ensure predictable fiscal effects amid rising drug spend (US prescription spend ~576B in 2023).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients \u0026amp; Caregivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePatients and caregivers seek therapies that slow decline and preserve function, prioritizing measurable outcomes; in the U.S. 6.7 million people were living with Alzheimer’s in 2023, driving strong demand for disease-modifying options. They need support for access and adherence—digital programs can improve adherence by ~15–25%—and benefit from clear expectations, monitoring, and active involvement in advocacy networks.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFocus: slowing decline, preserving function\u003c\/li\u003e\n\u003cli\u003eAccess: high need—6.7M US Alzheimer’s (2023)\u003c\/li\u003e\n\u003cli\u003eAdherence: digital programs +15–25%\u003c\/li\u003e\n\u003cli\u003eEngagement: active in advocacy\/networks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharma Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharma partners seek co-development and regional rights, preferring de-risked assets with validated biomarkers to shorten timelines and reduce clinical risk. They provide capital and commercial capabilities to fund late-stage development and enable market access; in 2024 the global pharma market was about $1.6 trillion, highlighting commercial upside. Partnerships drive portfolio synergies across indications and regions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCo-development \u0026amp; regional rights\u003c\/li\u003e\n\u003cli\u003ePreference for de-risked assets, biomarker-validated\u003c\/li\u003e\n\u003cli\u003eProvide capital \u0026amp; commercial capabilities\u003c\/li\u003e\n\u003cli\u003eEnable portfolio synergies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNeurology stakeholders align: clinicians, hospitals, payers and pharma pushing DMT adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNeurologists (6.7M AD, 1.2M PD US, 2024) drive prescribing; hospitals\/Centers (~6,000 hospitals, \u0026gt;150 academic centers; EHR adoption 96%) manage pathways; payers demand RWE and cost‑effectiveness; patients seek function‑preserving DMTs; biopharma partners provide capital (global pharma ≈$1.6T 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eNeurologists\u003c\/td\u003e\n\u003ctd\u003ePrevalence\u003c\/td\u003e\n\u003ctd\u003e6.7M AD \/ 1.2M PD\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical trial expenses cover site fees, monitoring, patient recruitment and data management, with imaging, biomarker assays and central lab work adding multi‑million dollar line items; CRO oversight and safety reporting further inflate operational budgets. In 2024, late‑stage programs routinely exceed $100 million, driving sharply higher per‑program spend as trials scale and complexity rises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCMC \u0026amp; Manufacturing Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProcess development, scale-up and validation typically drive early CMC spend, with tech transfer and PPQ activities often costing $1–5M per program; GMP production runs commonly range $0.5–2M per batch. Quality testing and cold-chain logistics add 5–15% to finished-product costs, while inventory management raises working-capital needs during scale-up.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eR\u0026amp;D \u0026amp; Preclinical Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiscovery, translational studies and in vivo models drive core preclinical spend, typically $20–40M in 2024 per program; biomarker development and assay validation add $3–7M. Platform improvements for C1q targeting require $5–10M, while publication and IP support cost roughly $0.5–2M, yielding total R\u0026amp;D\/preclinical outlays around $30–60M.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSG\u0026amp;A \u0026amp; Market Preparation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSG\u0026amp;A \u0026amp; Market Preparation covers medical affairs, access strategy and a limited field build to support early launches, alongside HEOR studies and patient services infrastructure; these drive high fixed costs and staged commercial spend for a rare-disease biotech with ongoing operating losses in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMedical affairs and access: formulary and payer engagement\u003c\/li\u003e\n\u003cli\u003eHEOR: real-world and cost-effectiveness studies\u003c\/li\u003e\n\u003cli\u003ePatient services: hub, support, reimbursement\u003c\/li\u003e\n\u003cli\u003eCorporate\/legal\/admin: governance and compliance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory \u0026amp; Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and compliance costs cover submission preparation and agency interactions, with US PDUFA FY2024 application fees at $3,117,200 and substantial CRO coordination. Pharmacovigilance systems, audits and signal management require ongoing spend supported by global safety teams and vendor platforms. Risk management plans and potential REMS add incremental program costs, while local country compliance for trials and launch demands country-specific filings and inspections.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubmission fees: PDUFA FY2024 $3,117,200\u003c\/li\u003e\n\u003cli\u003eSafety \u0026amp; audits: ongoing vendor and audit budgets\u003c\/li\u003e\n\u003cli\u003eREMS\/Risk plans: program-level incremental costs\u003c\/li\u003e\n\u003cli\u003eLocal compliance: country-specific filing\/inspection expenses\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-stage trials \u0026gt;$100M drive 2024 costs; preclinical $20-40M, CMC $1-5M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eClinical trials drive the largest line item, late‑stage programs \u0026gt;$100M in 2024; preclinical R\u0026amp;D typically $20–40M per program. CMC\/process scale-up costs $1–5M plus batch runs $0.5–2M and 5–15% testing\/logistics. Regulatory fees include PDUFA FY2024 $3,117,200; SG\u0026amp;A and market prep create high fixed costs during staged launches.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost Category\u003c\/th\u003e\n\u003cth\u003e2024 Range (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate‑stage trials\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;100,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical\/R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e20,000,000–40,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC\/Scale‑up\u003c\/td\u003e\n\u003ctd\u003e1,000,000–5,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP batch\u003c\/td\u003e\n\u003ctd\u003e500,000–2,000,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePDUFA fee\u003c\/td\u003e\n\u003ctd\u003e3,117,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting\/logistics\u003c\/td\u003e\n\u003ctd\u003e+5–15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProduct Sales (Post-Approval)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNet sales would derive from approved C1q-targeting therapies, distributed via specialty channels with potential premium pricing. Orphan indications typically yield high per-patient revenues, often exceeding $200,000–$500,000 annually. Specialty distribution supports higher gross-to-net realization versus mass channels. Approval for additional labels expands the treatable population and total addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMilestones from Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMilestones include upfront payments plus development, regulatory, and sales-triggered payments structured to fund clinical and CMC activities; 2024 top-tier biotech deals commonly feature upfronts plus contingent payments totaling tens to hundreds of millions, with risk-sharing aligning partner incentives and allowing global or regional deal structures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties on Licensed Rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTiered royalties on partnered geographies\/indications typically range 5–15% as of 2024, with higher bands for premium markets. These provide long-duration cash flows often spanning 10–15 years post-launch. Contracts can include sales-growth escalators (commonly +1–3% above $500m annual sales). Royalty streams are auditable and contractually protected via third-party audits, escrow mechanics and IP covenants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrants \u0026amp; Non-Dilutive Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGrants and non-dilutive funding from government and foundations underpin Annexon’s rare-disease programs, financing early IND-enabling studies and biomarker development, validating the scientific approach while preserving equity. NIH FY2024 appropriations totaled about $49.6 billion, a key source for rare-disease grant programs that reduce the need for equity financing and limit shareholder dilution.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupports rare-disease R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003eFunds early studies \u0026amp; biomarkers\u003c\/li\u003e\n\u003cli\u003eValidates science\u003c\/li\u003e\n\u003cli\u003eReduces shareholder dilution\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNamed-Patient \u0026amp; Early Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNamed-patient and early-access programs provide pre-approval revenue or cost recovery in select markets; as of 2024 Annexon had no commercial product revenue, making these channels strategically important. They generate real-world safety and effectiveness data and build clinician goodwill. Programs are tightly governed to satisfy local regulations and can bridge patients and payers into a broader commercial launch.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-approval cost recovery\u003c\/li\u003e\n\u003cli\u003eReal-world data \u0026amp; clinician goodwill\u003c\/li\u003e\n\u003cli\u003eRegulatory governance\u003c\/li\u003e\n\u003cli\u003eBridge to commercial launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eC1q orphan drugs: \u003cstrong\u003e$200k–$500k+\u003c\/strong\u003e pricing; 5–15% royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNet sales from approved C1q therapies target specialty channels with premium orphan pricing ($200k–$500k+\/patient\/year). Partner deals: 2024 upfronts plus milestones often total tens–hundreds of millions; royalties 5–15% with +1–3% escalators. Grants (NIH FY2024 ~$49.6B) and named-patient programs reduce dilution and provide RWD pre-launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRevenue Type\u003c\/th\u003e\n\u003cth\u003e2024 Benchmarks\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan pricing\u003c\/td\u003e\n\u003ctd\u003e$200k–$500k+\/pt\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDeal economics\u003c\/td\u003e\n\u003ctd\u003eUpfronts + tens–$100sM milestones\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e5–15% (±1–3% escalators)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"PESTEL Analysis","offers":[{"title":"Default Title","offer_id":58097850286428,"sku":"annexonbio-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0938\/8127\/0620\/files\/annexonbio-business-model-canvas.png?v=1781788278","url":"https:\/\/pestel-analysis.com\/products\/annexonbio-business-model-canvas","provider":"PESTEL ANALYSIS","version":"1.0","type":"link"}